OCU400
Gene Therapy Target: NR2E3
Ocugen
Most recent annual filing: 2026-03-04
- Governance/Authorized Shares corporate updateOct 26, 2026Governance/Authorized Shares corporate update, Oct 26, 2026, routine
- Corporate governance / cap tableOct 26, 2026Corporate governance / cap table, Oct 26, 2026, routine
- OCU400 Ph3 topline1Q 2027OCU400 Ph3 topline, 1Q 2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (12 active programs)
OCU410ST
Gene Therapy Target: RORA
OCU410
Gene Therapy Target: RORA
OCU200
Protein Target: integrin receptors
NeoCart
- Knee Cartilage Injuries
OCU500
Gene Therapy Target: SARS-CoV-2 Spike protein
OCU510
Gene Therapy Target: influenza
OCU520
Technology platforms
Novel Modifier Gene Therapy Platform · CanSino Biologics
Nuclear hormone receptor (NHR)-based modifier gene therapy platform using AAV5 vector delivery to retinal tissue; targets NR2E3 and RORA to address multiple inherited retinal diseases including retinitis pigmentosa, Stargardt disease, and dry AMD/geographic atrophy with a gene-agnostic approach
Targets: NR2E3, RORA
Inhaled Mucosal Vaccine Platform · Washington University in St. Louis
Next-generation inhalation-based mucosal vaccine platform based on a novel ChAd vector; designed to generate local mucosal immunity in the nasopharyngeal region for respiratory infectious diseases including COVID-19 and influenza
Targets: SARS-CoV-2 Spike protein, influenza
modifier gene therapy platform
Gene-agnostic modifier gene therapy platform designed to address underlying disease biology by restoring balance across multiple gene networks rather than targeting single gene mutations; focus areas include inherited retinal diseases and other blindness causes such as retinitis pigmentosa, Stargardt disease, and geographic atrophy
Targets: NR2E3
Biotech Distilled coverage (16)
- 2026-10-07 UPDATE: Ocugen (OCGN) - Adjourned Again 🔒 Paid
- 2026-09-23 UPDATE: Ocugen (OCGN) - The Unlock Gets Postponed 🔒 Paid
- 2026-09-02 UPDATE: Ocugen (OCGN) – First Patient Dosed in ArMaDa3 🔒 Paid
- 2026-08-07 UPDATE: Ocugen (OCGN) – The Rolling BLA Rolls Away 🔒 Paid
- 2026-07-30 UPDATE: Ocugen (OCGN) – RMAT Lands, BlackRock Shows Up, Stock Doesn’t Care 🔒 Paid
- 2026-07-13 UPDATE: Ocugen (OCGN) – The Second Regional Deal Lands 🔒 Paid
- 2026-06-11 UPDATE: Ocugen (OCGN) – The Annual Meeting That Didn’t Mention the Reverse Split
- 2026-05-15 UPDATE: Ocugen (OCGN) – The Greenshoe Gets Pulled, The CMO Walks 🔒 Paid
- 2026-05-06 UPDATE: Ocugen (OCGN) – The Convert Prices, The Arb Sells, The Stock Bleeds 🔒 Paid
- 2026-05-04 UPDATE: Ocugen (OCGN) – The Fortress Gets Built (On Borrowed Bricks)
- 2026-04-27 UPDATE: Ocugen (OCGN) – The Reverse Split Cometh 🔒 Paid
- 2026-03-29 UPDATE: Ocugen (OCGN) - Phase 2 GA Data Drops – The Receipts Are In 🔒 Paid
- 2026-03-22 UPDATE: Ocugen (OCGN) – The Smart Money Shrugs Off the Delaware Drama 🔒 Paid
- 2026-03-08 UPDATE: Ocugen (OCGN) – 2025 Fiscal Year Update 🔒 Paid
- 2026-01-22 CORRECTION & UPDATE: Ocugen (OCGN) Pays the Piper
- 2026-01-21 Ocugen inc. (OCGN): Scientific Deep Dive for OCU400 and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.